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Abstract
Background: To evaluate whether weekly schedules of docetaxel-based chemotherapy were superior to 3-weekly
ones in terms of quality of life in locally advanced or metastatic breast cancer.
Methods: Patients with locally advanced or metastatic breast cancer, aged ≤ 70 years, performance status 0-2,
chemotherapy-naive for metastatic disease, were eligible. They were randomized to weekly or 3-weekly
combination of docetaxel and epirubicin, if they were not treated with adjuvant anthracyclines, or docetaxel and
capecitabine, if treated with adjuvant anthracyclines. Primary end-point was global quality of life change at 6-
weeks, measured by EORTC QLQ-C30. With two-sided alpha 0.05 and 80% power for 35% effect size, 130 patients
per arm were needed.
Results: From February 2004 to March 2008, 139 patients were randomized, 70 to weekly and 69 to 3-weekly arm;
129 and 89 patients filled baseline and 6-week questionnaires, respectively. Global quality of life was better in the
3-weekly arm (p = 0.03); patients treated with weekly schedules presented a significantly worsening in role
functioning and financial scores (p = 0.02 and p < 0.001). Neutropenia and stomatitis were worse in the 3-weekly
arm, where two toxic deaths were observed. Overall response rate was 39.1% and 33.3% in 3-weekly and weekly
arms; hazard ratio of progression was 1.29 (95% CI: 0.84-1.97) and hazard ratio of death was 1.38 (95% CI: 0.82-2.30)
in the weekly arm.
Conclusions: In this trial, the weekly schedules of docetaxel-based chemotherapy appear to be inferior to the 3-
weekly one in terms of quality of life in patients with locally advanced or metastatic breast cancer.
Trial registration: ClinicalTrials.gov NCT00540800.
Background
Chemotherapy is a cornerstone of the treatment of
advanced breast cancer. Taxanes represent, together
with anthracyclines, a class of drugs with very strong
evidence of efficacy. Particularly, docetaxel is effective
both against locally advanced and metastatic breast
cancer, either as single-agent [1-5] or in combination
with other drugs, like anthracyclines [6-9] or capecita-
bine [10]. However, with such combinations, the most
common side effects are myelo-suppression and its
complications, neutropenic fever and/or infection. While
docetaxel is usually given every 3 weeks, a weekly sche-
dule was proposed to improve the toxicity profile of the
drug, particularly neutropenia and febrile neutropenia,
without decreasing antitumoral activity [11,12]. In meta-
static breast cancer, weekly docetaxel as single agent
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any medium, provided the original work is properly cited.was active and well tolerated, also in elderly patients and
in those with deteriorated performance status [13,14];
similarly, combinations of weekly docetaxel with epirubi-
cin or capecitabine are also characterized by a favourable
toxicity profile and antitumor activity [15,16]. Particu-
larly, weekly docetaxel and capecitabine have demon-
strated preclinical antitumor synergy; this synergy is
thought to occur from docetaxel-mediated up-regulation
of thymidine phosphorylase, an enzyme responsible for
the relative tumor selectivity of capecitabine [17].
However, no comparison in terms of quality of life
between weekly and 3-weekly schedules of docetaxel-
based chemotherapy has been reported to date.
On these bases, we planned a phase III randomized
clinical trial to test whether a weekly schedule of doce-
taxel combined with either weekly epirubicin or capeci-
tabine was superior to standard 3-weekly scheduling in
terms of quality of life in patients with locally advanced
or metastatic breast cancer.
Methods
Eligibility criteria
Women with locally advanced or metastatic breast
cancer, aged ≤ 70 years, not previously treated with
chemotherapy for metastatic disease were eligible.
Patients were required to have an Eastern Cooperative
Oncology Group performance status of 0 to 2, adequate
bone marrow, (absolute granulocyte count ≥ 2,000/
mmc, platelets ≥ 100,000/mmc, haemoglobin ≥ 10 g/dl),
renal (serum creatinine ≤ 1.25 upper normal limit) and
liver (total bilirubin ≤ 1.5 times upper normal limit;
AST and ALT ≤ 1.25 upper normal limit in absence of
liver metastases and ≤ 2.5 times upper normal limit in
presence of liver metastases) function. Previous adjuvant
or neoadjuvant chemotherapy as well as previous endo-
crine therapy for metastatic disease was allowed. Radio-
therapy was allowed, either adjuvant or for metastatic
disease. Patients were excluded if they had a positive
history of other types of cancer (except for radically
resected carcinoma-in-situo ft h ec e r v i xo rn o n - m e l a -
noma skin cancer), had received docetaxel as adjuvant
chemotherapy, had symptomatic brain metastases, or
serious medical conditions potentially compromising
study participation. Pregnant or lactating women were
ineligible. All patients were required to provide written
informed consent; the Independent Ethical Committee
of the National Cancer Institute of Naples approved the
protocol (ClinicalTrials.gov NCT00540800).
Treatment schedules
Patients not previously treated with anthracyclines were
randomized to weekly or 3-weekly combination of doce-
taxel and epirubicin [15,18,19]; treatment schemes cho-
sen for locally advanced breast cancer patients had a
higher planned dose-intensity than those chosen for
those with metastatic disease. Patients pre-treated with
anthracyclines were randomized to weekly or 3-weekly
combination of docetaxel plus capecitabine [16,20].
Dose and schedule details are reported in Table 1.
Docetaxel was administered as 1-hour intravenous
infusion. Epirubicin was administered as 10 minutes
intravenous infusion, before docetaxel. Capecitabine was
administered orally. Treatment delays for a maximum of
3 weeks or dose reduction of chemotherapy of 25% or
50% following hematological or non-hematological toxi-
city were planned by protocol.
Premedication with orally prednisone, 50 mg in
3-weekly and 25 mg in weekly arm, was performed as
follows: at -12, -3 and -1 hours before chemotherapy
and at +12, +24 and +36 hours after every administra-
tion of chemotherapy. Prophylactic antiemetic treatment
with 5-HT3 antagonists was given from the first infu-
sion. Granulocyte colony-stimulating factor (G-CSF) was
administered at 5 mcg/kg/day subcutaneously in case of
grade 4 neutropenia until neutrophil count >2000/mm
3.
Prophylactic use of G-CSF was mandated for patients
with locally advanced breast cancer treated with
3-weekly docetaxel and epirubicin.
Baseline and treatment evaluations
Staging included history and physical examination, per-
formance status score, routine laboratory studies, ECG,
chest radiographs, abdomen ultrasound scan or com-
puted tomography, bone scan, skeletal radiographs (if
the bone scan was abnormal). Patients were monitored
weekly by complete hematology and before every cycle
with complete chemistry analyses, record of toxicity,
adverse events, and physical examination. Evaluation of
tumor response was performed after 3 and 6 cycles for
patients with metastatic disease: patients with major
response or stable disease continued treatment up to a
maximum of 6 courses. For patients with locally
advanced disease evaluation of tumor response was per-
formed after 4 cycles and thereafter surgery was
planned, if feasible.
Assessment of quality of life
Two instruments were applied: the European Organiza-
tion for Research and Treatment of Cancer Quality of
Life Core Questionnaire (EORTC QLQ-C30) and the
Daily Diary Card. The EORTC QLQ-C30 is a 30-item
self-reporting questionnaire [21]. It is composed of
5 multi-item functional subscales: physical, role, emo-
tional, social and cognitive functioning; three multi-item
symptom scales measuring fatigue, pain, and emesis; a
global health status subscale; and six single items to
assess financial impact and symptoms such as dyspnoea,
sleep disturbance, appetite, diarrhea, and constipation.
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[22]. For functioning scales (i.e. those exploring physical,
role, emotional, cognitive and social functioning and
global health status), the higher the value the better the
level of function. For symptoms scales and items, the
h i g h e rt h ev a l u et h ew o r s et h es e v e r i t yo fs y m p t o m s .
Questionnaires were administered before randomization
and 6 weeks after beginning of treatment in both arms.
The Daily Diary Card was designed by the Medical
Research Council Lung Cancer Working Party [23] to cap-
ture rapid and transient changes in health and quality of
life, which may occur on a day-to-day basis during cancer
treatment. Patients had to score 8 items (sleeping, mood,
well-being, level of activity, nausea, vomiting, appetite loss
and pain) daily, from day 1 (first day of chemotherapy
administration) to day 42 (first 6 weeks of treatment).
Assessment of objective response and toxicity
Response evaluation was performed according to
response evaluation criteria in solid tumor (RECIST).
Patients who stopped treatment because of death, toxi-
city or refusal before restaging were defined as non-
responders in the calculation of response rate.
Toxicity was evaluated according to National Cancer
Institute - Common Toxicity Criteria (NCIC-CTC) ver-
sion 2.0. For each type of toxicity, the worst degree
experienced throughout the treatment was computed
for each patient.
Calculation of dose-intensity
Total delivered dose (mg/m
2) was calculated by sum-
ming all delivered drug doses. Actual time on treatment
was calculated as the difference between the last date of
treatment administration and the date of treatment
start, considering the last cycle as lasting the planned
number of weeks. Dose intensity was calculated dividing
total dose by time on treatment and was expressed as
mg/m
2/week.
Study design and sample size
The study was designed as a single centre randomised
phase III study with quality of life as primary end-point.
Global health status scale of EORTC QLQ-C30 after six
weeks from the start of chemotherapy was used to plan
sample size.
A sample size of 130 in each group was required to
have 80% power to detect an effect size of 0,35 (i.e. a
difference between mean scores of global health status
equal to 35% of the standard deviation) after six weeks
of chemotherapy, using a two group t-test with a 0,050
two-sided significance level (nQuery Advisor
® 4.0, Sta-
tistical Solutions Ltd, Cork, Ireland). This difference,
although small, was considered of potential clinical
interest. Considering a small dropout rate, 280 overall
patients were planned.
Secondary endpoints included response rate, toxicity
and overall survival. Patients were randomly assigned to
the two arms of the trial in a 1:1 ratio. Randomization
was performed by means of a computer-driven minimi-
zation procedure. Stratification factors were: group of
treatment (locally advanced vs metastatic not pretreated
with anthracyclines vs metastatic previously treated with
anthracyclines), performance status (0 vs. 1 vs. 2) and
age (≤50, >50 years).
Table 1 Regimens and drug doses of control and experimental arms
Setting Treatment
Arm
Regimens Dose Schedule Reference
Locally advanced Control Epirubicin 75 mg/m², d 1 Every 3 weeks for 4
cycles
de Matteis A,
2002
Docetaxel 80 mg/m², d 1
Experimental Epirubicin 30 mg/m², dd 1-8-15 Every 4 weeks for 3
cycles
Wenzel C, 2002
Docetaxel 35 mg/m², dd 1-8-15
Metastatic, no previous anthracyclines Control Epirubicin 60 mg/m², d 1 Every 3 weeks for 6
cycles
Trudeau ME,
1999
Docetaxel 75 mg/m², d 1
Experimental Epirubicin 25 mg/m², dd 1-8-15 Every 4 weeks for 6
cycles
Wenzel C, 2002
Docetaxel 30 mg/m², dd 1-8-15
Metastatic, previously treated with
anthracyclines
Control Capecitabine 1000 mg/m², b.i.d., dd
1-14
Every 3 weeks for 6
cycles
Pronk LC, 2000
Docetaxel 75 mg/m², d 1
Experimental Capecitabine 625 mg/m², b.i.d., dd 5-
18
Every 4 weeks for 6
cycles
Nadella P, 2002
Docetaxel 35 mg/m², dd 1-8-15
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Since the study was stopped prematurely, analyses of effi-
cacy were definitely underpowered. For quality of life, the
primary end-point of the study, the actual size gives an 80%
power to detect an effect size of 48% for the experimental
arm with a two-sided significance level of 0.05. At 6 weeks,
mean differences from baseline values were calculated for
each domain or symptom, within the two treatment groups.
Differences from baseline scores were compared between
treatments by a multivariable linear regression model, with
treatment and baseline values as covariates. For Daily Diary
Card, the daily rate of patients falling into the two worst
scores was calculated for each item.
For secondary end-points only descriptive analyses were
performed. Response rate was defined as the number of
complete plus partial responses divided by the total num-
ber of patients enrolled in each comparison arm. Median
follow-up was calculated according to the inverted
Kaplan-Meier technique [24]. Progression-free survival
was defined as the interval between the date of randomiza-
tion and disease progression or death whichever occurred
first; patients alive and not progressive were censored at
the date of the last follow-up information. Overall survival
was defined as the interval from the date of randomization
and the date of death or the date of last follow-up infor-
mation for living patients. For both progression-free and
overall survival, median values and hazard ratios (HR) of
weekly vs 3-weekly arms were reported.
Data are presented for the whole series of patients and
scattered by the three subgroups defined by stage of dis-
ease and previous treatment with anthracyclines.
Results
Patient characteristics
From February 2004 to March 2008, 139 patients were
enrolled in the study, 70 in the weekly and 69 in the
3-weekly arm. The enrollment was slower than planned
and was definitively stopped following the publication of
the results of a trial that compared weekly vs 3-weekly
schedules of taxanes in adjuvant breast cancer, indicat-
ing that in adult patients docetaxel was more effective if
given every 3 weeks [25].
Two patients were lost, immediately after randomiza-
tion, in the weekly and one in the 3-weekly arm, respec-
tively, while one patient was found ineligible after
randomization in the weekly arm (Figure 1). Baseline
characteristics of the patients are well balanced between
the two arms, with the exception of ECOG performance
status ≥1 and visceral involvement that were slightly
more frequent in the weekly arm (Table 2).
Treatment compliance
Median average relative dose intensity of treatment was
similar in the two arms; 75% and 70% of patients
received all the planned therapy in the control and
experimental arms, respectively. The rate of patients
receiving all planned cycles of docetaxel and capecita-
bine was quite low in both the 3-weekly and weekly
arms (47.6% and 40.0%, respectively - see Additional
File 1).
Quality of life
Compliance with quality of life assessment was 94% and
70% in the 3-weekly and 97% and 62% in the weekly
arm, at baseline and 6 weeks, respectively. There was a
statistically significant (p = 0.03) difference in terms of
global quality of life scores favouring the control arm
(Table 3 and additional file 2a). Among the five func-
tional sub-scores of the EORTC QLQ-C30, patients
treated with weekly schedules presented a significantly
worsening in role functioning (p = 0.02). Among the
nine symptom sub-scores of the QLQ-C30 questionnaire
(Additional file 2b), no significant differences were
found between 3-weekly and weekly arms, except for
t h ef i n a n c i a ls u b - s c o r et h a tw a sw o r s ei nt h ew e e k l y
than in the control arm (p < 0.001).
Daily Diary Cards were compiled and delivered by 55
and 52 patients in the 3-weekly and by 51 and 46 in the
weekly arm, after 3 and 6 weeks, respectively. The rates
of patients falling into the two worst categories for each
item day by day (Figure 2) show that nausea and vomit-
ing had negligible impact in both arms. Daily profiles
were consistent with a negative impact of 3-weekly
treatment in the first week and the reverse during sub-
sequent weeks.
Tumor response and overall survival
Both therapeutic regimens showed similar antitumor
activity. The response rate was 39.1% (95% exact CI:
27.6-51.6) in the 3-weekly and 33.3% (95% exact CI:
22.2-46.0) in the weekly arm. Seven patients (10%)
showed a complete response in the 3-weekly and 2
patients (3%) in the weekly arm.
Median follow-up was 32.9 months in the 3-weekly and
33.0 months in the weekly arm. After 86 (64%) events, the
median progression-free survival was 15.2 months in the
3-weekly and 13.1 months in the weekly arm (HR = 1.29;
95% exact CI: 0.84-1.97). With regard to overall survival,
59 events were reported. The median overall survival was
42.9 months in the 3-weekly and 33 months in the weekly
arm (HR = 1.38; 95% exact CI: 0.82-2.30). Data on efficacy
are summarized in Table 4, where also data scattered by
treatment group are reported.
Toxicity
Hematological and non-hematological toxicities are
summarized in Table 5. Among hematological toxicities,
neutropenia was common and it was more frequent and
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(n = 139)
Assigned 3-weekly arm 
(n = 70)
Locally 
advanced 
(n = 22)
Assigned weekly arm 
(n = 69)
Metastatic, 
no anthra         
(n = 27)
Metastatic, 
with anthra         
(n = 21)
Locally 
advanced 
(n = 22)
Metastatic, 
no anthra         
(n = 26)
Metastatic, 
with anthra     
(n = 21)
Analyzed 
(n = 69)
Analyzed 
(n = 66)
Lost after 
randomization      
(n = 1)
Lost after 
randomization        
(n = 1)
Found ineligible   
or lost after 
randomization      
(n = 2)  
Figure 1 The CONSORT flowchart.
Table 2 Description of patients by treatment arm and clinical setting
Whole set Locally advanced Metastatic not pre-
treated with
anthracyclines
Metastatic pre-treated
with anthracyclines
3-weekly
N=6 9
Weekly
N=6 6
3-weekly
N=2 2
Weekly
N=2 0
3-weekly
N=2 6
Weekly
N=2 6
3-weekly
N=2 1
Weekly
N=2 0
Age, median (range), yrs 52 (33-
68)
50 (30-
69)
48 (33-
65)
45 (30-
66)
54 (34-
67)
53 (38-
66)
52 (36-68) 54 (31-69)
ECOG performance status, n (%)
0 60 (87.0) 49 (74.2) 21 (95.5) 19 (95.0) 21 (80.8) 16 (61.5) 18 (85.7) 14 (70.0)
1 7 (10.1) 15 (22.7) 1 (4.5) 1 (5.0) 4 (15.4) 9 (34.6) 2 (9.5) 5 (25.0)
2 2 (2.9) 2 (3.1) - - 1 (3.8) 1 (3.8) 1 (4.8) 1 (5.0)
ER or PgR positive, n (%) 40 (58.0) 38 (57.6) 10 (45.5) 7 (31.8) 17 (65.4) 19 (73.1) 13 (61.9) 12 (60.0)
Previous epirubicin, n (%) - - - - - - 21 (100) 20 (100)
neoadjuvant 3 (14.3) 1 (5.0)
adjuvant 18 (85.7) 17 (85.0)
both - 2 (10.0)
Dose of previous epirubicin, median (range), mg/
m²
- - - - - - 422 (340-
600)
485 (289-
779)
At least one target lesion, n (%) 53 (76.8) 45 (68.2) 22 (100) 17 (77.3) 20 (76.9) 17 (65.4) 11 (52.4) 11 (55.0)
Dominant site of disease, n (%)
soft tissues (chest wall, breast and nodes) 31 (44.9) 22 (33.3) 22 (100) 20 (100) 6 (23.1) 1 (3.8) 3 (14.3) 1 (5.0)
bone 6 (8.7) 4 (6.1) - - 5 (19.2) 2 (7.7) 1 (4.8) 2 (10.0)
viscera (including pleura) 32 (46.4) 40 (60.6) - - 15 (57.7) 23 (88.5) 17 (81.0) 17 (85.0)
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Mean baseline score (SD) Mean 6 weeks score (SD) Mean difference (SD)
3-weekly Weekly 3-weekly Weekly 3-weekly Weekly P value*
N = 48 N = 41 N = 48 N = 41
Global QoL 62.8 (22.8) 64.0 (21.2) 67.9 (16.0) 60.0 (19.0) 5.0 (26.0) -3.5 (20.5) 0.03
Functional scales
Physical functioning 86.3 (16.6) 81.9 (19.6) 82.3 (16.8) 78.0 (18.0) -4.0 (11.8) -3.9 (14.3) 0.64
Role functioning 84.7 (22.2) 79.3 (26.0) 84.0 (21.2) 72.0 (23.4) -0.7 (22.3) -7.3 (24.7) 0.02
Emotional functioning 59.2 (23.5) 60.4 (22.2) 71.5 (19.1) 64.8 (24.4) 12.3 (21.6) 4.5 (18.5) 0.055
Cognitive functioning 88.9 (14.7) 89.8 (21.0) 90.3 (14.9) 83.7 (23.7) 1.4 (19.1) -6.1 (18.5) 0.055
Social functioning 81.6 (21.5) 80.5 (25.0) 80.2 (26.6) 69.5 (28.6) -1.4 (32.8) -11.0 (29.7) 0.07
Symptoms
Pain 23.6 (27.9) 26.0 (25.3) 15.3 (19.1) 22.4 (19.9) -8.3 (23.8) -3.7 (19.9) 0.08
Loss of appetite 13.2 (23.6) 13.8 (23.5) 15.3 (21.7) 14.6 (21.1) 2.1 (29.5) 0.8 (24.1) 0.86
Constipation 13.9 (16.6) 15.4 (24.8) 17.7 (23.9) 20.0 (28.0) 4.3 (26.6) 5.8 (31.9) 0.71
Financial 18.8 (26.5) 19.5 (30.7) 15.3 (23.8) 35.0 (33.3) -3.5 (22.0) 15.4 (37.3) 0.0007
Fatigue 19.4 (19.7) 24.1 (25.0) 31.6 (19.0) 36.9 (20.6) 12.2 (16.0) 12.7 (26.1) 0.39
Nausea/vomiting 5.2 (12.0) 7.3 (14.5) 17.4 (25.0) 19.5 (22.6) 12.2 (24.0) 12.2 (21.4) 0.87
Sleeping disturbance 27.7 (28.9) 40.0 (31.3) 22.9 (26.8) 29.2 (32.2) -5.7 (28.1) -10.8 (28.6) 0.90
Diarrhoea 5.6 (14.3) 2.6 (9.0) 9.0 (17.9) 12.2 (20.8) 3.5 (19.7) 9.4 (20.2) 0.31
Dyspnoea 5.6 (12.6) 14.6 (25.9) 9.0 (16.5) 19.2 (21.2) 3.5 (15.7) 4.2 (25.2) 0.10
SD: standard deviation; * bold p-values are statistically significant.
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experienced febrile neutropenia. Conversely, no relevant
differences were observed in anaemia and thrombocyto-
penia between the two arms. Among non-hematological
toxicities, stomatitis was worse in the 3-weekly arm,
while no striking differences between the two arms were
found in other non-hematological toxicities. Two toxic
deaths were observed, both in the 3-weekly arm with
the combination of docetaxel and epirubicin: one
patient, 67 years old, with metastatic disease, suffered of
grade 4 anemia, neutropenia, thrombocytopenia and sto-
matitis after the third cycle of chemotherapy and died
for neutropenic infection; the other patient, 50 years
old, with locally advanced disease, died for rectal bleed-
ing nine days after the first cycle of chemotherapy. Data
of severe toxicity scattered by arm and treatment group
are reported in the Additional file 3.
Discussion and Conclusions
This study shows that weekly schedules of docetaxel
combined with epirubicin or capecitabine were worse
than the standard 3-weekly schedules in terms of global
quality of life, role functioning and financial scores,
despite the worse hematologic toxicity of the latter, as
first-line chemotherapy for locally advanced or meta-
static breast cancer. Daily quality of life profiles indicate
a positive impact of the weekly treatment only in the
first week, while it had a negative impact during subse-
quent weeks. No major differences in antitumor activity
were observed with both schedules.
Two randomized trials compared single-agent doce-
taxel used either every 3 weeks or weekly in patients
with metastatic breast cancer [26,27]. Tabernero et al
reported no differences in response rate, but less hema-
tological toxicity in the weekly arm, in a study with 83
randomized patients [27]. Rivera et al, in a study with
118 randomized patients, found a higher response rate
in the 3-weekly arm (35.6% vs 20.3%), but patients in
this arm experienced more toxicity and there was no
difference in progression-free and overall survival [26].
However, none of these two studies included a quality
of life assessment. In patients with early breast cancer,
Sparano et al. recently reported a randomized phase 3
trial comparing weekly versus 3-weekly docetaxel or
paclitaxel after doxorubicin plus cyclophosphamide: a
higher 5-year disease-free survival rate in the 3-weekly
docetaxel arm (81.2% versus 77.6%) was observed [25].
The quality of life of patients with cancer has been
identified as a relevant endpoint in research and clinical
practice [28]. The present study is, to our knowledge,
the first trial comparing weekly with 3-weekly schedules
of docetaxel-based chemotherapy with quality of life as
Table 4 Activity and efficacy by treatment arm and clinical setting
Whole set Locally advanced Metastatic not pre-
treated with
anthracyclines
Metastatic pre-treated
with anthracyclines
3-weekly
N=6 9
Weekly
N=6 6
3-weekly
N=2 2
Weekly
N=2 0
3-weekly
N=2 6
Weekly
N=2 6
3-weekly
N=2 1
Weekly
N=2 0
Objective response
Complete response, n 7 2 2 1 2 - 3 1
Partial response, n 20 20 997744
Stable disease, n 19 16 10 8 8 7 1 1
Progressive disease, n 5 9 - 1 2 4 3 4
Not evaluable (non
responding), n
1 8 1 9 1178 1 0 1 0
Response rate, % (95% exact
CI)
39.1 (27.6-
51.6)
33.3 (22.2-
46.0)
50.0 (28.2-
71.8)
50.0 (27.2-
72.8)
34.6 (17.2-
55.7)
26.9 (11.6-
47.8)
33.3 (14.6-
57.0)
25.0 (8.7-
49.1)
Progression free survival
Progressed patients, n (%) 42 (60.9) 44 (66.7) 6 (27.3) 6 (30.0) 18 (69.2) 20 (76.9) 18 (85.7) 18 (90.0)
Median, months (95% CI) 15.2 (11.8-
36.6)
13.1 (7.7-
22.4)
n.r. n.r. 11.9 (10.2-
36.6)
10.4 (6.2-
22.4)
9.1 (5.9-29.7) 6.2 (4.2-
14.4)
HR weekly vs 3 weekly (95%
CI)
1.29 (0.84-1.97) 1.10 (0.35-3.45) 1.29 (0.67-2.47) 1.52 (0.78-2.97)
Overall survival
Dead patients, n (%) 27 (39.1) 32 (48.5) 3 (13.6) 2 (10.0) 13 (50.0) 15 (57.7) 11 (52.4) 15 (75.0)
Median, months (95% CI) 42.9 (27.7-
na)
33.0 (25.2-
na)
n.r. n.r. 26.7 (21.2-
na)
28.5 (11.4-
na)
33.2 (16.3-
na)
28.8 (19.8-
na)
HR weekly vs 3 weekly (95%
CI)
1.38 (0.82-2.30) 0.78 (0.13-4.69) 1.41 (0.67-2.99) 1.54 (0.70-3.36)
n.r. = not reached.
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Page 7 of 10primary endpoint. At 6 weeks, which we chose as the
time-point for the primary analysis, there was a slight
imbalance in compliance with fewer questionnaires
returned in the weekly arm; in principle, this might
favour the weekly arm due to a positive selection bias.
But, given that our conclusions are in favour of the
3-weekly schedules, we don’t believe that this difference is
critical. Obviously, comparing treatments with different
schedules introduces difficulties in quality of life assess-
ment. The EORTC questionnaire explores patient’sf e e l -
ings during the last week; this might partially affect the
observed results, because the time chosen for evaluation
corresponded to therapy for the weekly and no therapy for
the 3-weekly arm. For this reason we added a daily diary
card, to describe as more clearly as possible the changes of
quality of life during the whole treatment period. The
observed results suggest that the choice of a weekly sche-
dule of docetaxel-based chemotherapy does not improve,
but even worsens quality of life of patients, although it is
associated with a decrease in haematological toxicity. Our
interpretation of this result is that the impact of the reduc-
tion of haematological side effects of weekly docetaxel
regimens is not enough to counterbalance personal, famil-
iar and social disadvantages associated with more frequent
admittance to hospital for weekly administration of
antineoplastic drugs. We acknowledge, however, that
the impact on familiar and social disadvantages might
be affected by regional variation of cancer treatment
logistic.
There are several potential limitations of our study. First,
the study was stopped prematurely and it is underpowered
according to initial plan. Early stopping was independent
of treatment effects, but was prompted by the slow accrual
rate and the publication of the results of the trial by Spar-
ano et al. [25] that made continuation unethical. However,
the sample size of our trial is among the largest reported
for studies evaluating quality of life in metastatic breast
cancer and the study actually has 80% power to detect a
48% improvement in quality of life, that is an effect of
medium size, that might be considered as clinically rele-
vant. Second, a questionable issue is that patients at differ-
ent stages of disease were eligible for the study; different
stages, in fact, may imply worse or better QoL levels; how-
ever, our plans were based on the consideration that, once
Table 5 Worst NCI-CTC grade of toxicity by patient, in the whole group of patients
3-weekly, n (%) Weekly, n (%)
Grade 0 1234 5 0 12 3 4 5
Allergy 68 (98,6) - 1 (1,4) - - - 65 (98,5) - 1 (1,5) - - -
Anaemia 48 (69,6) 13 (18,8) 7 (10,1) - 1 (1,4) - 49 (74,2) 8 (12,1) 7 (10,6) 2 (3,0) - -
Neutropenia 21 (30,4) - 3 (4,3) 19 (27,5) 26 (37,7) - 36 (54,5) 10 (15,2) 9 (13,6) 7 (10,6) 4 (6,1) -
Thrombocytopenia 66 (95,7) - 2 (2,9) - 1 (1,4) - 64 (97,0) 1 (1,5) - 1 (1,5) -
Febrile Neutropenia 67 (97,1) 1 (1,4) 1 (1,4) - 66 (100,0) - - -
Neutropenic infection 59 (85,5) 4 (5,8) 5 (7,2) - - 1 (1,4) 61 (92,4) 1 (1,5) 4 (6,1) - - -
Bleeding 66 (95,7) 2 (2,9) - - - 1 (1,4) 64 (97,0) 1 (1,5) - 1 (1,5) - -
Cardiac 61 (88,4) 6 (8,7) 1 (1,4) 1 (1,4) - - 59 (89,4) 4 (6,1) 2 (3,0) 1 (1,5) - -
Fatigue 43 (62,3) 16 (23,2) 10 (14,5) - - - 41 (62,1) 11 (16,7) 13 (19,7) 1 (1,5) - -
Fever 60 (87,0) 4 (5,8) 5 (7,2) - - - 62 (93,9) 2 (3,0) 1 (1,5) 1 (1,5) - -
Weight loss 69 (100,0) ---- - 6 4 (97,0) 1 (1,5) 1 (1,5) - - -
Hair loss 24 (34,8) 1 (1,4) 44 (63,8) 33 (50,0) 8 (12,1) 25 (37,9)
Cutaneous 60 (87,0) 3 (4,3) 4 (5,8) 1 (1,4) 1 (1,4) 51 (77,3) 8 (12,1) 6 (9,1) 1 (1,5) -
Conjunctivitis 66 (95,7) 1 (1,4) 2 (2,9) - - - 61 (92,4) 3 (4,5) 2 (3,0) - - -
Anorexia 67 (97,1) 2 (2,9) - - - 66 (100,0) - - - -
Constipation 63 (91,3) 4 (5,8) 2 (2,9) - - 63 (95,5) 2 (3,0) 1 (1,5) - -
Diarrhoea 53 (76,8) 9 (13,0) 6 (8,7) 1 (1,4) - - 56 (84,8) 6 (9,1) 4 (6,1) - - -
Dysgeusia 67 (97,1) 2 (2,9) - - 63 (95,5) 3 (4,5) - -
Nausea 26 (37,7) 25 (36,2) 17 (24,6) 1 (1,4) - 31 (47,0) 26 (39,4) 8 (12,1) 1 (1,5) -
Vomiting 46 (66,7) 14 (20,3) 7 (10,1) 1 (1,4) 1 (1,4) - 46 (69,7) 14 (21,2) 4 (6,1) 2 (3,0) - -
Stomatitis 39 (56,5) 18 (26,1) 8 (11,6) 2 (2,9) 2 (2,9) - 44 (66,7) 17 (25,8) 4 (6,1) 1 (1,5) - -
Abdominal pain 58 (84,1) 5 (7,2) 3 (4,3) 3 (4,3) - - 60 (90,9) 4 (6,1) 2 (3,0) - - -
Skeletal pain 64 (92,8) 1 (1,4) 4 (5,8) - - - 66 (100,0) - - - - -
Diabetes 69 (100,0) ---- - 6 3 (95,5) - 1 (1,5) 1 (1,5) 1 (1,5) -
Hepatic 64 (92,8) 4 (5,8) 1 (1,4) - - - 57 (86,4) 8 (12,1) 1 (1,5) - - -
Neurologic 62 (89,9) 6 (8,7) - 1 (1,4) - - 59 (89,4) 5 (7,6) - 1 (1,5) 1 (1,5) -
Pulmonary 69 (100,0) ---- - 6 4 (97,0) 2 (3,0) - - - -
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Page 8 of 10balance is warranted through randomization and stratifica-
tion, the comparison should not be biased. Similar considera-
tions can be done for the heterogeneity of chemotherapeutic
regimens used at the different stages. Third, the evidence of
efficacy of some of the treatments schedules chosen for this
trial was quite low; however, this limitation might also be
interpreted as a value of the present trial that provides some
more evidence on treatment schedules proposed as promis-
ing and no longer studied, like the combination of weekly
docetaxel and capecitabine [16]. Thanks to randomization,
our data suggest that this weekly combination is less promis-
ing than expected.
The results of the present study should not be gener-
alized to weekly regimens with other drugs, such as
paclitaxel, that has shown a superior efficacy compared
to paclitaxel every 3 weeks, both in adjuvant and in
metastatic setting, with a different toxicity profile
[25,29]. Similarly, the results of this study should not be
generalized to different subpopulations of breast cancer
patients; weekly docetaxel has proven active and extre-
mely well tolerated among elderly breast cancer patients,
a population that would be at risk of toxicity with stan-
dard 3-weekly scheduling [30,31]. In conclusion, in our
study the weekly schedules of docetaxel-based che-
motherapy appeared to be inferior to the 3-weekly ones
in terms of quality of life, among adult patients with
locally advanced or metastatic breast cancer and should
not be preferred for clinical practice.
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